Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
Дата публикации: 07-10-2026 07:00:00

Evidence for efficacy is based on the results from the EXCALIBER-RRMM study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma012.1430-09-2026
2Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer09.7424-08-2026
3Un nuevo paradigma del mieloma múltiple con más calidad de vida06.4805-10-2026
4Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma 09.2516-12-2025
5EMA recommends extension of indications for pirtobrutinib08.8625-09-2026
6FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer014.7923-09-2026
7Anito-cel, a d-domain BCMA CAR T-cell, induces rapid, deep, and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma023.7905-10-2026
8Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma 07.1420-04-2026
9FDA разрешило SystImmune клинические испытания биспецифического препарата SI-B037014.7629-09-2026
10Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS08.7130-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 15.43. Источник: www.esmo.org.